Document Classification

Section Type: RESULTS

Text: Similar results were obtained when the analysis was restricted to trials with a polymeric stent platform (Treatment of de novo coronary disease using a single pAclitaXel elUting Stent [TAXUS] - I, - II, - IV, and - VI) (RR = 1. 01, 95 % CI 0. 40 to 2. 53, p = 0. 99), trials with longer lesions (TAXUS-IV and - VI) (RR = 0. 62, 95 % CI 0. 2 to 1. 91, p = 0. 41), and trials that used a higher dose of paclitaxel (ASian Paclitaxel-Eluting Stent Clinical trial [ASPECT], European evaLUaTion of paclitaxel Eluting Stents [ELUTES], and DELIVER-I) (RR = 1. 87, 95 % CI 0. 52 to 6. 81, p = 0. 34).